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R5 viruses reveals robust entry of infectious HIV-1
cores into macrophages
Petra Mlcochova1, Sarah A Watters1, Greg J Towers1,2, Mahdad Noursadeghi1,2 and Ravindra K Gupta1,2*Abstract
Background: It is now known that clinically derived viruses are most commonly R5 tropic with very low infectivity
in macrophages. As these viruses utilize CD4 inefficiently, defective entry has been assumed to be the dominant
restriction. The implication is that macrophages are not an important reservoir for the majority of circulating viruses.
Results: Macrophage infection by clinical transmitted/founder isolates was 10-100 and 30-450 fold less efficient as
compared to YU-2 and BaL respectively. Vpx complementation augmented macrophage infection by non-
macrophage tropic viruses to the level of infectivity observed for YU-2 in the absence of Vpx. Augmentation was
evident even when Vpx was provided 24 hours post-infection. The entry defect was measured as 2.5-5 fold, with a
further 3.5-10 fold block at strong stop and subsequent stages of reverse transcription as compared to YU-2. The
overall block to infection was critically dependent on the mechanism of entry as demonstrated by rescue of
infection after pseudotyping with VSV-G envelope. Reverse transcription in macrophages could not be enhanced
using a panel of cytokines or lipopolysaccharide (LPS).
Conclusions: Although the predominant block to clinical transmitted/founder viruses is post-entry, infectivity is
determined by Env-CD4 interactions and can be rescued with VSV-G pseudotyping. This suggests a functional link
between the optimal entry pathway taken by macrophage tropic viruses and downstream events required for
reverse transcription. Consistent with a predominantly post-entry block, replication of R5 using viruses can be
greatly enhanced by Vpx. We conclude therefore that entry is not the limiting step and that macrophages represent
clinically relevant reservoirs for ‘non-macrophage tropic’ viruses.
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Macrophages are thought to be important cellular targets
of HIV infection due to their access to multiple tissue
compartments and relative longevity even when produc-
tively infected with HIV (reviewed in [1]). There has been
renewed interest in HIV infection of macrophages across
clinical and basic science disciplines, driven by two factors.
Firstly, recognition of neurocognitive disease in the post
HAART era [2] and its association with compartmenta-
lized CNS viral replication [3-5]. Secondly, the rise of the
‘eradication’ agenda will inevitably need to address macro-
phages as intermediate or long-term reservoirs [5,6].* Correspondence: ravindra.gupta@ucl.ac.uk
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distribution, and reproduction in any mediumEarly observations that some CCR5 using laboratory
viruses such as YU-2 (cloned directly from the central
nervous system tissue) efficiently infected macrophages
led to conflation of the terms CCR5 tropism and macro-
phage tropism [7]. This dogma has been challenged by
work demonstrating that R5 tropic envelopes are diverse
in their ability to replicate in monocyte derived macro-
phages [8]. More specifically, envelope glycoproteins
(Envs) from viruses isolated from central nervous system
often confer efficient macrophage replication upon pseu-
dotyping viruses as compared to Envs from blood or
lymph nodes in patients with neurocognitive disease
[9,10], and since then a diverse range of envelope deter-
minants have been implicated in this phenotype, often
associated with the CD4 binding site [11-13].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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mised by both recombination and biased sampling [14],
more recent studies have used single genome amplification
(SGA) to overcome this limitation [15,16]. Furthermore,
use of Env alone neglects the role of other parts of the gen-
ome in envelope expression and infectivity, for example
Nef and Gag [17-19]. Recently, and after significant invest-
ment, a panel of clinical full genome subtype B and C iso-
lates has become available [15,20-22]. The sequences are
from early infection and have been derived using SGA and
sequencing. These clones represent the most appropriate
clinical isolates for HIV research gained thus far. Studies on
these viruses have shown that inefficient macrophage infec-
tion (compared to prototypic macrophage tropic viruses) is
prevalent, and indeed the norm in both transmitted
founder (T/F) viruses and viruses derived during chronic
infection [15,21,23]. Given that viral determinants map to
Env, the assumption has been that the entry event repre-
sents the dominant restriction.
SAMHD1 was recently identified as an anti-HIV restric-
tion factor in myeloid lineage cells (dendritic cells and mac-
rophages) acting at post-entry step of the virus life-cycle
[24,25]. SAMHD1 is a dNTP hydrolase thought to limit re-
verse transcription (RT) through decreasing levels of
dNTPs [26]. This mammalian protein is the target of the
lentiviral accessory gene vpx, found in HIV-2/SIVsm lineage
viruses, but not in the SIVgsn lineage or HIV-1/SIVcpz
[24]. Vpx, akin to other viral countermeasure proteins such
as Vpu and Vif, degrades its target restriction factor via a
ubiquitin dependent proteasomal pathway [24,25].
In this study we demonstrate that infectivity of a panel
of ‘non-macrophage tropic’ clinical isolates is rescued by
Vpx complementation in macrophages. We show that
the dominant restriction is at early RT and that this in-
fection block is determined by Env-CD4 interactions
and can be rescued with VSV-G pseudotyping.
Results
Clinically derived transmitted/founder viruses are rescued
by Vpx
The available panel of three subtype C and three subtype
B full-length clinically derived viruses (Table 1) were de-
rived from plasma in individuals with acute infectionTable 1 Details of single genome derived infectious molecula
Virus Location of patient Gender T
ZM246F Zambia F H
ZM247F Zambia F H
ZM249M Zambia M H
CH040 USA M M
CH058 USA M M
CH077 USA M M
Key: MSM: men who have sex with men; Fiebig stage is a serological staging system[27] following mucosal transmission, representing trans-
mitted/founder (T/F) viruses [15]. These viruses were
previously reported to replicate poorly in spreading in-
fection in MDM [15,23]. We show here that in contrast
to T cells (where similar infectivity was detected across
all viruses tested; Additional file 1: Figure S1), all clinic-
ally derived viruses tested in MDM showed lower infec-
tion when compared to macrophage tropic viruses such
as YU-2 or BaL over a single round of infection. Using
intracellular p24 staining 48 h post-infection, we de-
tected 10-100 or 30-450 fold lower infection of MDM
for T/F viruses compared to YU-2 or BaL, respectively
(Figure 1A). Furthermore, we found substantial differences
between clinical isolates, for example ZM249M and CH040
differed by almost one order of magnitude compared to
ZM246F, ZM247F or CH077. Nevertheless, there was no
statistically significant difference in MDM infection be-
tween subtype B and C clinically derived viruses (p = 0.70).
We tested the sensitivity of T/F viruses to Vpx
(Figure 1B) by adding VSV-G pseudotyped SIV virions
containing Vpx to MDM at the same time as virus in-
oculum. Six hours post-infection cells were washed and
new medium was added to the culture. Complementa-
tion with Vpx increased infection of MDM by at least
one order of magnitude for all viruses tested, including
YU-2. Interestingly, Vpx complementation augmented
macrophage infection for three of the T/F viruses
(ZM246F, ZM247F and CH077) to the level of YU-2 in
the absence of Vpx (Figure 1B). We further explored
whether infection of MDM could be rescued after virus
inoculation. We infected MDM with two clinically de-
rived viruses (CH058 and CH077) and complemented
with Vpx at various intervals post-infection (4, 6, 10,
24 h). Cells were fixed and stained for intracellular p24
protein 48 h post-infection. We observed a rescue me-
diated by Vpx at all time points tested up to 24 h post-
infection (Figure 1C) in these experiments. These data
demonstrate that (i) clinically derived T/F viruses are as
sensitive to Vpx as the widely used macrophage tropic
strain (YU-2), (ii) the rescue of T/F viruses infection
mediated by Vpx can be very potent and can reach in-
fection similar to macrophage tropic viruses, (iii) rescue
can be achieved even 24 hours post-infection.r clones and host demographic characteristics
ransmission type Fiebig stage HIV-1 subtype
eterosexual II C
eterosexual II C
eterosexual IV C
SM II B
SM II B
SM II B
for defining the timing of infection.
Figure 1 Vpx rescues T/F viruses to a similar extent as that seen for YU-2 in macrophages. (A) Monocyte derived macrophages (MDM)
were infected with equal amounts of p24 of macrophage tropic viruses YU-2, BaL and subtype C and B full-length viruses for 6 h. Cells were
washed and new medium was added. MDM were fixed and labeled for intracellular p24 48 h post-infection. Data shown are mean of three
independent experiments and error bars represent the standard deviation. (B) MDM were infected as in (A) with or without 1 ng of SIVmac
particles containing Vpx. Cells were washed after 6 h and new medium was added. Intracellular p24 staining was analyzed 48 h post-infection.
Graph shows representative data of two independent experiments each in duplicates. Error bars represent the standard deviation. White bars:
infection without Vpx; black bars: infection with Vpx. Numbers above the graph show fold difference between infection in presence (vpx) and
absence (-vpx) of vpx VLP. (C) MDM were infected with CH077 (white bars) and CH058 (checked bars) clinically derived viruses for 4 h and Vpx
was added at different time points. All MDM were fixed and stained for intracellular p24 at 48 h post-infection. No Vpx: MDM were infected for
4 h, washed and new medium added. 0 h: MDM were infected with virus and complemented with Vpx at the same time for 4 h, washed and
new medium was added; 4 h, 6 h, 10 h, 24 h: MDM were infected with virus for 4 h, washed and new medium was added; Vpx was added at
4 h, 6 h, 10 h and 24 h following the infection. Graph shows representative data of two independent experiments each in duplicates. Error bars
represent the standard deviation.
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single round replication difference between YU-2 and
clinical strains, consistent with an independent block.
Macrophage entry is only modestly impaired in
‘non-macrophage tropic’ isolates
It was suggested, though not proven, that the T/F virus
phenotype of low replication capacity in macrophages
maps probably to a virus entry defect. That notion is para-
doxical to our data showing potent Vpx rescue infection.
We decided to (i) investigate if T/F virus infection is
dependent on cell surface CD4 levels (as previous work
suggested that the T/F strains are less sensitive to soluble
CD4 [23]) and (ii) directly measure entry efficiency of
full-length T/F viruses in both T cell lines and MDM.
Macrophages are known to express lower levels of
CD4 than CD4+ T cells [28], and envelopes from ‘non-
macrophage tropic’ HIV strains have been reported to
utilize these low levels inefficiently (reviewed in [29]).
We tested if the replication block detected in MDM is
dependent on CD4 cell surface levels. We used 293-
Affinofile cells whose surface levels of CD4 and CCR5can be manipulated pharmacologically. These cells were
maximally induced to express CCR5 at the cell surface
and at the same time induced to express low or high
levels of CD4 (Figure 2A,B), as previously described
[30]. Cells were infected with normalized virus stocks
and infection measured 48 h later by flow cytometry. All
clinically derived viruses as well as YU-2 were able to in-
fect cells with high levels of CD4 to the same extent
(Figure 2B, black bars). Nevertheless, in target cells ex-
pressing low levels of CD4 (Figure 2B, white bars), infec-
tion was reduced by approximately ten fold in clinical
isolates as compared to YU-2, largely recapitulating find-
ings in macrophages (Figure 1A). To demonstrate de-
pendence of virus infection on both CD4 and CCR5
levels in this assay system, we used YU-2 and ZM247F
viruses to infect 293-Affinofile cells (Figure 2C) expres-
sing variable levels of both receptors. Infection by both
viruses was sensitive to increases in both CD4 and
CCR5 expression levels. However, at the lowest level of
CD4 expression, increasing CCR5 levels could partially
rescue infection by YU-2 (10 fold increase) but not
ZM247F (Figure 2C). These results suggest that the
Figure 2 Full-length transmitted/founder viruses use low levels of the cells surface CD4 inefficiently. (A) A representative flow cytometry
experiment showing CD4 expression levels on minimally (low) and maximally (high) induced 293-Affinofile cells in comparison with CD4+
primary T cells. (B) Equal amounts of p24 of YU-2 and clinically derived transmitted viruses were used to infect 293-Affinofile cells, which were
maximally induced to express high levels of CCR5 and high (black bars) or low (white bars) levels of CD4. Cells were washed, fixed,
permeabilized with saponin and stained with anti-HIV-1 p24 FITC-conjugated monoclonal antibody 48 h post-infection. Percentage infection was
determined by flow cytometry. Data are representative of at least two independent experiments and error bars represent the standard deviation.
(C) 293-Affinofile cells were induced to express different cell surface levels of CD4 and CCR5. Cells were infected with 50 ng of p24 of YU-2 and
ZM247F and percentage of infection determined by flow cytometry. Data shown are representative example of three independent experiments.
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CD4 cell surface levels.
To investigate the entry efficiency of full-length T/F vi-
ruses in both the T cell line CEM.NKR-CCR5-Luc and
MDM we used the well established BlaM-Vpr assay [31].
We consistently found a 2.5-4.5 fold reduction in macro-
phage entry but not T cell entry when comparing T/F vi-
ruses to YU-2 and BaL (Figure 3A and B). As there was at
least 10-100 fold (compared to YU-2) or 30-450 fold
(compared to BaL) difference in single round macrophage
infection (Figure 1A,B), this modest entry defect implied a
possible further post-entry block to the T/F viruses. Also,
measurement of total viral DNA using qPCR showed a
much larger difference between YU-2 and a representative
T/F virus CH077 (54 fold difference) when entry was
again only modestly affected (4.5 fold, Figure 3C).
To rule out sensitivity of the entry assay as a contribu-
tory factor in the observed phenotype, we firstly aimed to
demonstrate a direct and consistent correlation between
fusion and accumulation of RT products for a given virus
across a range of input doses and thereby a range of entry
event frequencies. In this experiment BlaM-Vpr contai-
ning viruses were used to infect MDM at two different
input doses (80 and 480 ng of p24 as determined by p24
ELISA). We detected a 2.5 fold difference in virus entryand 1.6 fold difference in total viral DNA between the
two doses of YU-2 BlaM-Vpr virus used (p = NS)
(Figure 3D). Similarly, BaL BlaM-Vpr virus showed a 4.5
fold difference in virus entry assay and a 3 fold differ-
ence in total DNA between the two viral doses (p = NS)
(Figure 3E). Secondly, we excluded non-envelope medi-
ated entry into MDM using Env-deficient HIV-1 subtype
C ZM247Fv1Δenv virus and ZM247Fv1Δenv complemen-
ted in trans with YU-2 envelope (Additional file 2: Figure
S2). Finally, we adjusted p24 amounts of YU-2 and two
T/F viruses (CH077 and CH058) to achieve the same
entry efficiency and measured intracellular p24 in infected
MDM 48 h later. Interestingly, even though entry was the
same we still detected an additional block to infection (3-4
fold) between YU-2 and T/F viruses (Figure 3F). Taken to-
gether these data confirm the correlation between virus
entry and RT products detected by our assays and
although T/F viruses show detectable entry defect into
macrophages, this defect seems not to account for the
overall low replication in macrophages.
Reverse transcription is the primary block to clinical
isolates
Having established that a modest entry defect appears to
result in disproportionately compromised total DNA
Figure 3 Transmitted/founder viruses display modestly reduced entry efficiency in MDM. (A,B) CEM.NKR-CCR5-Luc cells (CEM) or MDM
were infected with equal amounts of p24 of BlaM-Vpr containing viruses for 4 h. Cells were loaded with CCF2/AM dye and fusion events were
detected by flow cytometry using BD LSR Fortessa, and gated from 10,000 cells. (A) A representative example of three independent experiments.
Percentage in each panel represents virus fusion positive cells (cleaved CCF2). (B) Graph shows a percentage of detected fusion events (blue cells)
normalized to YU-2 as a control (100%), and represents an average of three independent experiments, each conducted in triplicate. Black bars
represent CEM cells and white bars MDM. (C) MDM were infected with equal amounts of p24 of BlaM-Vpr containing viruses for 4 h. Cells were
inspected for virus entry as described above, at the same time cells were harvested at 6 h post-infection for total DNA isolation and total viral
DNA was determined using quantitative PCR.% blue cells or copies/100 ng DNA are normalized to YU-2 (100%). (D,E) MDM were infected with
equal amounts of p24 of YU-2 (D) or BaL (E) BlaM-Vpr containing viruses for 4 h. Cells were inspected for virus entry as described above, at the
same time cells were harvested at 6 h post-infection for total DNA isolation and total viral DNA was determined using quantitative PCR.% blue
cells or copies/100 ng DNA are normalized to higher p24 input of virus (480 ng ~ 100%). (F) MDM were infected with different amounts of p24 of
BlaM-Vpr containing viruses to achieve equal virus entry for 4 h. Inspected for entry efficiency and also labeled for intracellular p24 48 h
post-infection.% blue cells and infected cells/field are normalized to YU-2 (100%). (C-F) Data shown are representative example of at least two
independent experiments conducted in duplicates. Error bars represent the standard deviation.
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life cycle the block occurs. We infected MDM with a
full-length clinical isolate, determined infection by intra-
cellular p24 staining at 48 h post-infection (Figure 4A)
and extracted total DNA at 0, 6 and 18 h post-infectionfor qPCR measurement of RT products (Figure 4B,C).
Infection was reduced in the CH077 clinical isolate when
compared to YU-2 (15 fold, Figure 4A), and accordingly
there was a 20 fold difference in total HIV-1 DNA
(Figure 4B). Interestingly, early viral DNA products
Figure 4 Reverse transcription is additionally impaired in clinically derived transmitted/founder viruses. MDM were from the same donor
infected with equal amounts of p24 YU-2 and CH077 viruses. (A) MDM were fixed and stained for intracellular p24 protein 48 h post-infection.
(B,C) MDM were harvested and total DNA was isolated at 0 h, 6 h and 18 h post-infection. Viral DNA products were detected using quantitative
PCR. (B) total DNA; (C) strong stop. This is a representative example of three independent experiments on different donors. The YU-2:CH077 ratio
represents fold difference in infection or viral DNA copies numbers between these viruses.
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nitude, suggesting that the defect in RT is caused early in
T/F viral life cycle. Moreover, this defect is evident early
on (detected at 6 h) and did not change with time, sug-
gesting that later steps of RT were not additionally im-
paired. We confirmed a consistent difference in early viral
RT products (strong-stop) in multiple donors for two dif-
ferent T/F viruses (CH058, CH077) (Additional file 3:
Figure S3). Together these data show that the difference
in products of RT seems to be in concordance with the in-
fection defect as assessed by intracellular p24 capsid pro-
tein (Figure 4A-C), and that clinically derived viruses are
subject to post-entry restriction in macrophages relative
to the macrophage tropic virus YU-2.The block to reverse transcription is not dissociable from
entry using VSV-G
In order to explore whether the entry and RT defects
were dissociable from each other, we pseudotyped full-
length YU-2, CH058 and CH077 with VSV-G glycopro-
tein and infected MDM with equal amounts of each
virus. Intracellular p24 staining of MDM determined at
48 h post-infection (Figure 5A) showed equal overall in-
fection for T/F viruses compared to YU-2. We detected
a 4-8 fold difference in strong-stop and total viral DNA
products at 6 h post-infection (p < 0.05), though this dif-
ference disappeared at 18 h post-infection (Figure 5B,C)
(p = NS).Lack of evidence for tissue factors able to rescue RT
The tissue environment in vivo might contain factors
which could mimic the effect of Vpx and relieve the
post-entry block to clinically derived viruses. It would be
important to know if post-entry viral cores within MDM
could complete RT and infection, if the host macrophage
were to enter a “conducive” environment such as lym-
phoid tissue. We tested this hypothesis by using a panel
of stimuli encountered by macrophages in vivo during
primary HIV infection [32], such as TNFα, interferon γ
and β, ΜIP-1α and lipopolysaccharide (LPS). Furthermore
we investigated the possible role of CCL19 (a CCR7
ligand), which has been suggested to play a role in pro-
moting entry, RT and integration in unactivated T cells
[33]. As our hypothesis was promotion of post-entry
viral replication steps, we infected the cells with two
clinically derived viruses and YU-2 for 6 h and after
washing cells, used new medium supplemented with
the indicated cytokines and LPS. Cells were examined
for intracellular p24 staining 48 h post-infection. We
did not observe significant changes in p24 production.
The only exception was IFN-β, which caused significant
decrease in infection of all three viruses tested, consis-
tent with previous data [34] (Figure 6).
Discussion
Macrophages are long-lived cells and have access to pri-
vileged anatomical sites. They are therefore potentially
important cellular reservoirs. Macrophage tropic viruses
Figure 5 Blocks to entry and reverse transcription are not dissociable from one another. MDM from the same donor were infected with
equal amounts of p24 VSV-G glycoprotein pseudotyped YU-2, CH058 and CH077 viruses. (A) MDM were fixed and stained for intracellular p24
protein 48 h post-infection. (B,C) MDM were harvested and total DNA was isolated at 0 h, 6 h and 18 h post-infection. Viral DNA products were
detected using quantitative PCR. (B) total DNA; (C) strong stop. This is a representative example of three independent experiments on
different donors.
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tive disease [4,35], but it is increasingly apparent that
plasma derived viruses, even those able to use CCR5 re-
ceptors, replicate inefficiently in this cell type. We have
sought to understand this apparent paradox by studying
macrophage infection using viruses derived using SGA.Figure 6 Cytokines or LPS are not able to recapitulate the
effect of Vpx in single round infection of MDM. MDM were
infected with equal amounts of p24 of YU-2 and subtype B
full-length viruses CH077 and CH058 for 6 h. Cells were washed and
new medium was added along with interferon beta (IFN-β; 5000U/
ml), interferon gamma (IFN-γ; 20 ng/ml), LPS (100 ng/ml), tumor
necrosis factor (TNF-α ; 10 ng/ml), MIP-1α (0.1 μg/ml), or CCL19
(100 ng/ml). This is a representative example of at least two
independent experiments.All six full-length clinically derived transmitted/founder
viruses studied showed low macrophage infection in sin-
gle round infection compared to the macrophage tropic
HIV-1 strain YU-2 or BaL, which have an intermediate
to high tropism for macrophages [15].
Here we report for the first time that the sensitivity of
clinically derived T/F viruses to Vpx complementation is
similar to that described for laboratory strains [26,36].
Moreover, we showed that Vpx increased infection of all
the T/F viruses in MDM by a similar magnitude as com-
pared to YU-2. We observed differences in the level of
infection in MDM after Vpx complementation between
individual T/F viruses, although there was no statistically
significant difference in Vpx mediated augmentation be-
tween subtype B and C viruses (p = 0.23). Surprisingly,
rescue could be achieved even 24 h post-infection, ar-
guing against the recently suggested nuclease activity
for SAMHD1 acting on incoming viral RNA [37].
Although we have tested T/F viruses, envelopes from
clinically derived chronic viruses show similar low levels
of macrophage infection and therefore we believe our
findings are also relevant to chronic infection [38]. Even
though we were able to rescue extremely low infection in
macrophages through Vpx complementation, there was
still at least a 10 fold difference between infection by YU-2
and T/F clinical viruses in the presence of Vpx. Based on
previous assumptions that low replication capacity in
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should not have been rescued in our experiment.
Given that infection of T/F viruses in macrophages is
not well defined, we proceeded to investigate this in a
comprehensive way. We demonstrate that the block to
infection in macrophages is sensitive to CD4 cell surface
levels using Affinofile cells [31]. This cell assay system
has not previously been used to examine the panel of
full-length clinical isolates with Env expressed from the
cognate provirus. Consistent with inefficient CD4 use,
we confirmed there was a 2.5-4.5 fold reduction in viral
entry to macrophages compared to YU-2 or BaL. This
entry defect did not account for the whole replication
defect of T/F viruses in MDM. We performed multiple
controls showing that observed fold differences in MDM
infection between T/F viruses and YU-2 or BaL cannot
be related to problems with resolution of the entry assay
relative to the RT qPCR assay, but rather represents an
additional early post-entry block. This block seems to be
at early RT or post-entry step. Importantly, this finding
is in concordance with previous early reports: Potash
et al. assessed fusion/entry in alveolar macrophages
using a dequenching assay, revealing less than two fold
difference between the AD8 macrophage tropic isolate
and a ‘T-tropic isolate’, despite a much greater difference
in cDNA and p24 production [39]. Also both the Desro-
siers and Fauci laboratories concluded that the dominant
restriction in human macrophages of SIVmac239 and
the ‘T cell tropic’ virus 92 MW959 is determined by the
viral envelope, but not at virus entry itself in macro-
phages [40,41]; post entry restriction was reported for
the X4 viruses LAI and NDK in macrophages though
entry was not assessed [42] and the predominant block
was reported as being at nuclear translocation. Finally,
the McKnight and Overbaugh groups have observed Env
dependent post entry restriction in cell lines [43-45].
We demonstrate that the entry and RT blocks are not
dissociable for currently circulating R5 using HIV strains,
using VSV glycoprotein pseudotyped viral particles. These
data suggest the post-entry restriction of T/F viruses in
macrophages is largely dependent on the route of entry
and interaction of viral envelope with CD4 receptor and
co-receptors. VSV-G pseudotyping mediates viral entry
through endocytosis, bypassing the requirement for the
cell surface receptor CD4 and co-receptors CCR5 or
CXCR4. Interestingly, HIV-1 envelope has been reported
to induce intracellular signaling in CD4+ T cells to support
viral replication [46,47]. Our observations are also highly
reminiscent of data demonstrating that increases in sur-
face CCR5 expression can lead to disproportionately large
RT changes compared to entry changes [48], possibly re-
lated to signaling via calcium influx [41]. We speculate
that inefficient CD4 and CCR5 usage by viruses (such as
T/F viruses) may not only influence membrane fusion andentry, but also downstream events such as reverse tran-
scription through intracellular signaling cascades. Interest-
ingly, the actin cytoskeleton has been proposed as a
barrier to RT [49], with depolymerizing agents able to in-
crease infectivity and compensate for Nef deleted virus
[50], as can VSV-G pseudotyping [51,52]. We are cur-
rently investigating the role of the actin cytoskeleton on
T/F infection in macrophages.
Our study has important reservoir implications. Even
though T/F viruses are inefficient in infecting MDM
there is still low-level infection which, as we demon-
strated, can be rescued by Vpx. It might be possible that
subsequent changes in macrophage environment and
state, for example activation due to concurrent infection
or other inflammatory processes, might trigger changes
that allow initiation of productive infection in vivo
[53,54]. We therefore tested a panel of cytokines which
might be encountered by macrophages in vivo during
primary HIV infection [32]. Although none of these
molecules showed any effect on clinically derived T/F vi-
ruses or YU-2 in a single round infection, there are likely
to be tissue factors in vivo with similar post-entry effects
as Vpx on HIV in macrophages.
There has been considerable controversy regarding the
first targets of HIV infection following mucosal expos-
ure, with CD4+ T cells and macrophages being the pri-
mary candidates. The realization that founder viruses
were poorly macrophage tropic has resulted in a shift in
the balance of opinion in favour of T cells. Our data
showing that the virus core/reverse transcription com-
plexes indeed enter the macrophage and are intact and
biologically competent transform the discussion. In the
transmission setting, occult infection of macrophages at
the mucosa might occur without antigen presentation,
with subsequent ‘reactivation’ in lymph nodes and
efficient spread to other cell types.
Conclusions
We propose that HIV-1 infected patients are likely at
any given time to have a proportion of macrophages that
contain HIV RNA/DNA species in the absence of pro-
ductive infection. These macrophages may represent a
reservoir and an important cellular target for HIV des-
pite low levels of p24 in vitro. A greater understanding
of macrophage infection using relevant viruses may be
critical in curative strategies, which to date have focused
largely on reactivation of latently infected T cells to tar-
get the HIV reservoir.
Methods
Reagents, antibodies, plasmids
Tissue culture media and supplements were obtained
from Invitrogen (Paisley, UK), and tissue culture plastic
was purchased from TPP (Trasadingen, Switzerland). All
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USA) unless indicated otherwise. All infectious molecu-
lar clones were obtained from NIH AIDS Research and
Reference Reagent Program (Germantown, MD, USA).
Cell lines
293 T cells were cultured in DMEM complete (DMEM
supplemented with 100 U/ml penicillin, 0.1 mg/ml
streptomycin, and 10% FCS); 293-Affinofile cells were a
kind gift from Benhur Lee and cultured in DMEM
complete supplemented with 50 μg/ml of Blasticidin.
CEM.NKR-CCR5-Luc [55] were cultured in RPMI
complete (RPMI 1640, 100 U/ml penicillin, 0.1 mg/ml
streptomycin, and 10% FCS) supplemented with 0.8 μg/ml
of Gentamycin.
Generation of virus stocks
Virus stocks were generated by DNA plasmid transfec-
tion of 293 T using Fugene HD (Promega UK Ltd, UK)
according to the manufacture’s protocol. The VSV-G-
pseudotyped virus was produced by co-transfection of
293 T with pMDG plasmid and YU-2, CH058 and
CH077 HIV-1 molecular clones. Viral supernatant were
harvest 48 h post-transfection, filtered through 0.45 μm
pore-size filters and stored at -80°C. Clarified viral super-
natant were analyzed by p24 ELISA (AIDS and Cancer
Virus Program NCI-Frederick, MD, USA) for HIV-1 p24
antigen concentration and infectivity of virus stocks also
compared using TZMBL indicator cells. Virus like parti-
cles containing Vpx were prepared as previously de-
scribed [36].
Monocyte isolation and differentiation
PBMC were prepared from HIV seronegative donors
(after informed consent was obtained), by density-
gradient centrifugation (Lymphoprep, Axis-Shield, UK).
Monocyte-derived macrophages (MDM) were prepared
by adherence with washing of non-adherent cells after
2 h, with subsequent maintenance of adherent cells in
medium containing RPMI 1640 supplemented with 10%
human AB serum (Sigma) and MCSF (10 ng/ml) for
3 days and then cultured for further 4 days in RPMI
1640 supplemented with 10% human AB serum.
Infection of primary cells
1 × 105 MDM were infected with 50 ng of p24 of each
virus for 6 h at 37˚C. Cells were washed in PBS and new
medium was added. MDM were fixed in ice cold
acetone-methanol (1:1 [vol/vol]) 2 days post-infection,
and infected cells identified by staining for p24 protein
using a 1:1 mixture of the anti-p24 monoclonal anti-
bodies EVA365 and EVA366 (NIBSC, Center for AIDS
Reagents, UK) and a secondary goat anti-mouse beta-
galactosidase-conjugated antibody (SouthernBiotech, AL,USA), and visualized by X-Gal (5-bromo-4-chloro-3-
indolyl-β-d-galactopyranoside) staining (Promega). In-
fected cells were detected by light microscopy and
counted as number of infected (blue) cells per inspected
field.
Induction and infection of 293-Affinofile cells
CD4 and CCR5 expression on the cell surface was in-
duced as described previously [30]. Briefly, expression of
CD4 was induced by doxycycline (0.1 ng/ml for low and
20 ng/ml for high CD4 expression) and CCR5 expres-
sion by ponasterone A (2 μM for high CCR5 expression)
at 37˚C for 18 h. Cells were infected with 50 ng of p24
of each virus and spinoculated at 1200 g/2 h, room
temperature. The infection medium was replaced with
DMEM complete supplemented with 50 μg/ml of Blasti-
cidin, and the cells were incubated for 48 h. Cells were
washed, fixed in 3% paraformaldehyde, permeabilized
with saponin and stained with anti HIV-1 p24 FITC-
conjugated monoclonal antibody (Insight Biotechnology
LTD, UK). Percentage of infection was determined by
flow cytometry using BD FACSCalibur (BD Biosciences,
UK) and analyzed by CellQuest (BD Biosciences) and
FlowJo software (Tree Star, OR, USA).
Measurement of HIV-1 entry (BlaM-Vpr assay)
MDM or CEM.NKR-CCR5-Luc cells were infected with
100 ng of HIV-1 virions containing BlaM-Vpr. Cells
were spinoculated at 1200 g/2 h and further incubated
for additional 2 h at 37˚C, 5%CO2, washed in CO2-inde-
pendent medium and then loaded with CCF2-AM dye
(Invitrogen) according to manufacture’s protocol in
CO2-independent medium supplemented with 2.5 mM
Probenicid (organic anion transport inhibitor). Cells
were incubated for 1 h at room temperature, washed
twice in CO2-independent medium and BlaM reaction
was allowed to develop for 16 h in CO2-independent
medium supplemented with 2.5 mM Probenicid at room
temperature. Cells were washed in PBS, fixed in 3%
paraformaldehyde and monitored by flow cytometry.
Change in emission fluorescence of CCF2 (green to
blue) after cleavage by the beta-lactamase (BlaM) was
analyzed using BD LSRFortessa (BD Biosciences), FACS-
DIVA software (BD Biosciences) and FlowJo software
(Tree Star).
Quantitative PCR for early RT products
2 × 105 MDM were infected with 100 ng of p24 of
DNaseI-treated viruses for 0, 6, 18 h. Cell were washed
and harvested for DNA isolation. Total DNA was ex-
tracted using the Qiagen DNeasy kit (Qiagen Ltd., UK)
with the following modifications, cells were lysed in AL
buffer and Proteinase K for 30 minutes at 56˚C and nu-
cleic acids were eluted in 45 μl nuclease free molecular
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10 minutes before centrifugation. 100 ng of DNA was ana-
lyzed by quantitative real time PCR for each of the follo-
wing PCRs; total HIV DNA, strong stop DNA products.
All reactions were performed in duplicate.
Primers and probe previously described [56] were used to
detect strong stop products: oHC64 (TAACTAGGGAACC-
CACTGC) and oHC65 (GCTAGAGATTTTCCACACTG)
and probe oHC66 (FAM-ACACAACAGACGGGCACA-
CACTA-TAMRA). A final reaction contained Qiagen
Quantitect Probe PCR master mix, 900nM of each pri-
mer and 250nM of probe. Cycling conditions were 95°C
for 15 min, followed by 40 cycles of 15 s at 95°C and
1 min at 60°C. The reaction was performed on an
Eppendorf Mastercycler ep realplex (Eppendorf UK
Limited, UK). A dilution series of a YU-2 full-length
molecular clone was used to create a standard curve.
Total HIV DNA quantitation
Primers and probe were used to detect total DNA by
amplifying the region between LTR and gag:HIV1LTR1
(GCCTCAATAAAGCTTGCCTTGA),HIV1LTR2:(GGC
GCCACTGCTAGAGATTTT) and HIV1LTRPR (FAM -T
GTGACTCT GGTAACTAGAGATCCCTCAGAC-TAM
RA). Additionally primers and probe for human pyru-
vate dehydrogenase (PDH) were duplexed in the reac-
tion as an internal control. The primers and probe are
as follows: PDH1 (TGAAAGTTATACAAAATTGAGG
TCACTGTT),PDH2(TCCACAGCCCTCGACTAACC),
PDHPR (JOE-CCCCCAGATACACTT AAGGGATCA
ACTCTTAATTGT-TAMRA). A final reaction con-
tained Qiagen Multiplex PCR kit, 100nM each of the
PDH primers and both the PDH and LTR probe as well
as 200nM of LTR primers. Cycling conditions were 95°C
for 15 min, followed by 45 cycles of 1 min at 94°C and
1 min at 60°C. The reaction was performed on an
Eppendorf Mastercycler ep realplex. Extracted DNA
from the 8E5 cell line, which contains one defective pro-
virus per cell [57], was quantified and a dilution series
was used to create a standard curve for both PDH and
LTR-Gag.
Statistical analysis
Student’s t-test was used to compare means. Statistical
analyses were carried out in GraphPad Prism 5 (GraphPad
Software Inc., La Jolla, California, USA).
Additional files
Additional file 1: Figure S1. Similar infectivity across all viruses tested
in primary T cells and the T cell line. Primary CD4+ T cells were isolated
from PBMC using negative selection with antibody-coated magnetic
beads (Miltenyi Biotec Ltd., UK) and stimulated for 3 days in the presence
of PHA (at 2ug/ml) and IL-2 (at 10 pg/ml) in RPMI medium supplementedwith 10% fetal calf serum. CD4+ T cells and CEM.NKR-CCR5-Luc (T cell
line) expressing both CD4 and CCR5 receptors were infected with equal
amounts of p24 of control virus YU-2 and subtype C and B full-length
viruses for 6 hours. Cells were washed and new medium was added. (A)
Supernatants from infected CD4+ T cells were collected and analyzed
using p24 ELISA assay 4 days post-infection. (B) CEM.NKR-CCR5-Luc cells
were lysed by adding Steady-Glo luciferase reagent (Promega, UK) 3 days
post-infection and luminescence was read using a GloMax 96
Luminometer (Promega, UK). Data shown are mean of three independent
experiments and error bars represent the standard deviation.
Additional file 2: Figure S2. MDM infection by Env deficient virus. (A)
MDM were infected with equal amounts of p24 of BlaM-Vpr containing
viruses for 4 h. Cells were loaded with CCF2/AM dye and fusion events
were detected by flow cytometry using BD LSR Fortessa, and gated from
10,000 cells. Percentage in each panel represents virus fusion positive
cells (cleaved CCF2). (B) MDM were infected with 50 ng of p24 of virus
for 4 h. Cells were washed in PBS and new medium was added. MDM
were fixed in ice cold acetone-methanol (1:1 [vol/vol]) 48 h post-
infection, and infected cells identified by staining for intracellular p24
protein. Un-infected: un-infected control; ZM247Fv1Δenv: envelope
deficient virus; ZM247Fv1Δenv + YU-2: envelope deficient virus
complemented with YU-2 envelope. Data shown are representative
example of two independent experiments.
Additional file 3: Figure S3. Early reverse transcription efficiency. MDM
from three different donors were infected with equal amount of p24
YU-2, CH058 and CH077 for 6 h. Cells were harvested and total DNA was
isolated. Early viral DNA products were detected (strong stop) using
quantitative PCR (see in methods: Quantitative PCR for early RT products).
All the experiments were conducted in duplicate.
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